| Literature DB >> 25969895 |
Martin Behrens1, Anett Mau-Moeller2, Matthias Weippert3, Josefin Fuhrmann1, Katharina Wegner2, Ralf Skripitz2, Rainer Bader2, Sven Bruhn1.
Abstract
This study investigated effects of caffeine ingestion (8 mg/kg) on maximum voluntary torque (MVT) and voluntary activation of the quadriceps during isometric, concentric and eccentric contractions. Fourteen subjects ingested caffeine and placebo in a randomized, controlled, counterbalanced, double-blind crossover design. Neuromuscular tests were performed before and 1 h after oral caffeine and placebo intake. MVTs were measured and the interpolated twitch technique was applied during isometric, concentric and eccentric contractions to assess voluntary activation. Furthermore, normalized root mean square of the EMG signal was calculated and evoked spinal reflex responses (H-reflex evoked at rest and during weak isometric voluntary contraction) as well as twitch torques were analyzed. Caffeine increased MVT by 26.4 N m (95%CI: 9.3-43.5 N m, P = 0.004), 22.5 N m (95%CI: 3.1-42.0 N m, P = 0.025) and 22.5 N m (95%CI: 2.2-42.7 N m, P = 0.032) for isometric, concentric and eccentric contractions. Strength enhancements were associated with increases in voluntary activation. Explosive voluntary strength and voluntary activation at the onset of contraction were significantly increased following caffeine ingestion. Changes in spinal reflex responses and at the muscle level were not observed. Data suggest that caffeine ingestion induced an acute increase in voluntary activation that was responsible for the increased strength regardless of the contraction mode.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25969895 PMCID: PMC4429543 DOI: 10.1038/srep10209
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Peak twitch torques, evoked potentials, maximum voluntary torque (MVT), voluntary activation, normalized muscle activity during MVT (RMS-EMGMVT/Mmax), rate of torque development (RTD) and normalized muscle activity during RTD (RMS-EMGRTD/Mmax) in the time interval 0–200 ms for the caffeine (CAF) and placebo trial (PLA) obtained at baseline.
| 16.8 ± 10.4 | 17.7 ± 10.2 | −0.9 | |
| 38.6 ± 18.7 | 39.6 ± 18.1 | −1.0 | |
| 1.72 ± 1.10 | 2.32 ± 1.96 | −0.60 | |
| 7.84 ± 3.87 | 7.86 ± 3.11 | −0.02 | |
| 0.21 ± 0.12 | 0.24 ± 0.15 | −0.03 | |
| 2.29 ± 2.13 | 1.94 ± 1.57 | 0.35 | |
| 7.46 ± 3.68 | 6.78 ± 2.90 | 0.68 | |
| 0.26 ± 0.14 | 0.26 ± 0.13 | 0.00 | |
| 3.21 ± 1.53 | 3.09 ± 1.12 | 0.12 | |
| 6.20 ± 4.58 | 6.69 ± 4.64 | −0.49 | |
| 198.7 ± 37.4 | 211.3 ± 46.0 | −12.6 | |
| 165.2 ± 42.0 | 179.6 ± 43.7 | −14.4 | |
| 203.5 ± 35.2 | 203.3 ± 40.4 | 0.2 | |
| 72.3 ± 10.2 | 73.8 ± 11.4 | −1.5 | |
| 65.9 ± 12.7 | 68.5 ± 14.3 | −2.6 | |
| 62.2 ± 5.6 | 62.7 ± 11.3 | −0.5 | |
| 0.086 ± 0.019 | 0.085 ± 0.018 | 0.001 | |
| 0.062 ± 0.027 | 0.056 ± 0.017 | 0.006 | |
| 0.109 ± 0.033 | 0.114 ± 0.037 | −0.005 | |
| 0.088 ± 0.032 | 0.085 ± 0.027 | 0.003 | |
| 0.081 ± 0.022 | 0.083 ± 0.020 | −0.002 | |
| 0.058 ± 0.025 | 0.054 ± 0.015 | 0.004 | |
| 0.102 ± 0.036 | 0.114 ± 0.042 | −0.012 | |
| 0.082 ± 0.032 | 0.082 ± 0.028 | 0.000 | |
| 0.081 ± 0.022 | 0.074 ± 0.010 | 0.007 | |
| 0.056 ± 0.028 | 0.051 ± 0.015 | 0.005 | |
| 0.100 ± 0.033 | 0.093 ± 0.021 | 0.007 | |
| 0.087 ± 0.028 | 0.078 ± 0.022 | 0.009 | |
| 623.5 ± 162.2 | 657.2 ± 188.3 | −33.7 | |
| 0.084 ± 0.021 | 0.084 ± 0.016 | 0.000 | |
| 0.063 ± 0.024 | 0.059 ± 0.019 | 0.004 | |
| 0.104 ± 0.036 | 0.107 ± 0.031 | −0.003 | |
| 0.086 ± 0.032 | 0.085 ± 0.023 | 0.001 | |
Diff.: difference between means, Hmax: maximal H-reflex at rest, Mmax: maximal M-wave at rest, Hsup: H-reflex during 10% of isometric MVT, Msup: maximal M-wave during 10% of isometric MVT, ISO: isometric, CON: concentric, ECC: eccentric. Data are means ± standard deviations.
Figure 1Effect of caffeine (CAF) on (A) maximum voluntary torque (iMVT), (B) voluntary activation and (C) normalized muscle activity of the quadriceps at MVT (Q RMS-EMGMVT/Mmax) during isometric, concentric and eccentric MVCs. ∗ denotes a significant difference between trials (ANCOVA with baseline-adjustment, ∗ P ≤ 0.05; ∗∗ P ≤ 0.01) and † denotes a statistical tendency towards a significant difference between trials (ANCOVA with baseline-adjustment, P ≤ 0.09). PLA: placebo trial
Figure 2Effect of caffeine (CAF) on (A) rate of torque development (RTD) and (B) normalized muscle activity (Q RMS-EMGRTD/Mmax). ∗ denotes a significant difference between trials (ANCOVA with baseline-adjustment, ∗ P ≤ 0.05). PLA: placebo trial
Peak twitch torques, evoked potentials, normalized muscle activity during maximum voluntary torque (RMS-EMGMVT/Mmax) and normalized muscle activity during rate of torque development (RMS-EMGRTD/Mmax) in the time interval 0–200 ms for the caffeine (CAF) and placebo (PLA) trial obtained at post-tests.
| 17.3 ± 2.1 | 16.5 ± 2.1 | 0.8 (−0.8 to 2.4) | 0.315 | |
| 40.5 ± 2.6 | 39.9 ± 2.6 | 0.6 (−1.5 to 2.6) | 0.608 | |
| 2.19 ± 1.32 | 1.77 ± 1.32 | 0.42 (−1.23 to 2.07) | 0.583 | |
| 7.85 ± 1.62 | 7.33 ± 1.62 | 0.52 (−0.74 to 1.78) | 0.404 | |
| 0.21 ± 0.05 | 0.21 ± 0.05 | 0.00 (−0.06 to 0.06) | 0.946 | |
| 1.67 ± 1.27 | 1.97 ± 1.27 | −0.30 (−1.34 to 0.73) | 0.547 | |
| 7.10 ± 2.01 | 7.14 ± 2.01 | −0.04 (−1.62 to 1.54) | 0.957 | |
| 0.20 ± 0.10 | 0.26 ± 0.10 | −0.06 (−0.14 to 0.02) | 0.163 | |
| 3.02 ± 0.44 | 3.10 ± 0.44 | −0.08 (−0.42 to 0.27) | 0.654 | |
| 6.05 ± 1.02 | 6.47 ± 1.02 | −0.42 (−1.21 to 0.38) | 0.288 | |
| 0.070 ± 0.019 | 0.062 ± 0.019 | 0.008 (−0.007 to 0.023) | 0.304 | |
| 0.122 ± 0.022 | 0.114 ± 0.022 | 0.008 (−0.011 to 0.026) | 0.291 | |
| 0.098 ± 0.019 | 0.084 ± 0.019 | 0.014 (0.000 to 0.030) | ||
| 0.066 ± 0.022 | 0.062 ± 0.022 | 0.004 (−0.012 to 0.021) | 0.572 | |
| 0.123 ± 0.030 | 0.105 ± 0.030 | 0.018 (−0.006 to 0.042) | 0.130 | |
| 0.091 ± 0.019 | 0.078 ± 0.019 | 0.013 (−0.003 to 0.028) | 0.107 | |
| 0.073 ± 0.020 | 0.060 ± 0.020 | 0.013 (−0.007 to 0.033) | 0.178 | |
| 0.106 ± 0.017 | 0.103 ± 0.017 | 0.003 (−0.015 to 0.019) | 0.797 | |
| 0.097 ± 0.018 | 0.076 ± 0.018 | 0.021 (0.004 to 0.038) | ||
| 0.066 ± 0.019 | 0.062 ± 0.019 | 0.04 (−0.009 to 0.018) | 0.494 | |
| 0.115 ± 0.022 | 0.104 ± 0.022 | 0.011 (−0.007 to 0.029) | 0.224 | |
| 0.099 ± 0.019 | 0.081 ± 0.019 | 0.018 (0.003 to 0.033) | ||
Diff. (95% CI): difference between means (95% confidence interval), Hmax: maximal H-reflex at rest, Mmax: maximal M-wave at rest, Hsup: H-reflex during 10% of isometric MVT, Msup: maximal M-wave during 10% of isometric MVT, ISO: isometric, CON: concentric, ECC: eccentric. Data are baseline-adjusted means ± baseline-adjusted standard deviations.
∗denotes a significant difference between groups (ANCOVA with baseline-adjustment, P ≤ 0.05) and
†denotes a statistical tendency towards a significant difference between groups (ANCOVA with baseline-adjustment, P ≤ 0.06).
Figure 3An overview of the procedures carried out during neuromuscular testing of the knee extensors and the extracted parameters. The thin arrow indicates electrical stimulation at submaximal intensity and the thick arrow indicates electrical stimulation at supramaximal intensity. Hmax: maximal H-reflex at rest, Mmax: maximal M-wave at rest, Hsup: maximal H-reflex at 10% of MVC strength during an isometric voluntary contraction, Msup: maximal M-wave at 10% of MVC strength during an isometric voluntary contraction, MVT: maximum voluntary torque, RTD: rate of torque development, RMS-EMG: root mean square of the EMG signal, ISO: isometric, CON: concentric, ECC: eccentric.